Literature DB >> 18534722

Long-term stability of Vero cell-derived inactivated Japanese encephalitis vaccine prepared using serum-free medium.

Hiroko Toriniwa1, Tomoyoshi Komiya.   

Abstract

We established a method of producing a Vero cell-derived Japanese encephalitis vaccine using serum-free medium, and tested its stability using various stabilizers during the inactivation process and storage at 4 degrees C and 28 degrees C. Similar to previously reported results of cell culture in serum-containing medium, Vero cells were cultured in a serum-free medium multiplied well, and the viral yield was successfully increased to about 10(9)PFU/ml. Following formalin-inactivation and purification via ethanol precipitation and sucrose density ultracentrifugation of the virus solution, the vaccine had the same quality as, and higher immunogenicity, the mouse brain-derived vaccine in current use. Testing of several stabilizers showed that the addition of 0.5% glycine during the virus inactivation process facilitated the maintenance of immunogenicity for a long period of time. Furthermore, the addition of 0.5% glycine and 1.0% sorbitol as vaccine stabilizers after purification led to the maintenance of immunogenicity for 1 year, not dependent on the storage temperature (4 degrees C or 28 degrees C). These results indicate that, in contrast to the current mouse brain-derived vaccine, the Vero cell-derived vaccine can be prepared using serum-free medium containing no animal-derived components, and that the vaccine can be stored at room temperature by adding stabilizers, suggesting the possibility of producing room temperature-stable vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18534722     DOI: 10.1016/j.vaccine.2008.04.076

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Real-time monitoring of adherent Vero cell density and apoptosis in bioreactor processes.

Authors:  Emma Petiot; Amal El-Wajgali; Geoffrey Esteban; Cécile Gény; Hervé Pinton; Annie Marc
Journal:  Cytotechnology       Date:  2012-02-25       Impact factor: 2.058

2.  Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children.

Authors:  Emmanuel Feroldi; Maria Rosario Capeding; Mark Boaz; Sophia Gailhardou; Claude Meric; Alain Bouckenooghe
Journal:  Hum Vaccin Immunother       Date:  2013-02-26       Impact factor: 3.452

3.  Carbohydrates-chitosan composite carrier for Vero cell culture.

Authors:  Ya-Ching Lin; Guan-Ting Chen; Sheng-Chi Wu
Journal:  Cytotechnology       Date:  2016-10-05       Impact factor: 2.058

4.  JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody.

Authors:  Maximilian Larena; Natalie A Prow; Roy A Hall; Nikolai Petrovsky; Mario Lobigs
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

5.  An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.

Authors:  Mario Lobigs; Megan Pavy; Roy A Hall; Päivi Lobigs; Peter Cooper; Tomoyoshi Komiya; Hiroko Toriniwa; Nikolai Petrovsky
Journal:  J Gen Virol       Date:  2010-02-03       Impact factor: 3.891

6.  An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody.

Authors:  Nikolai Petrovsky; Maximilian Larena; Venkatraman Siddharthan; Natalie A Prow; Roy A Hall; Mario Lobigs; John Morrey
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

7.  Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals.

Authors:  Helle Bielefeldt-Ohmann; Natalie A Prow; Wenqi Wang; Cindy S E Tan; Mitchell Coyle; Alysha Douma; Jody Hobson-Peters; Lisa Kidd; Roy A Hall; Nikolai Petrovsky
Journal:  Vet Res       Date:  2014-12-17       Impact factor: 3.683

8.  Recombinant Measles AIK-C Vaccine Strain Expressing the prM-E Antigen of Japanese Encephalitis Virus.

Authors:  Akira Higuchi; Hiroko Toriniwa; Tomoyoshi Komiya; Tetsuo Nakayama
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.